Asahi Kasei, Evotec Enter Ion Channel Discovery Pact

Evotec AG has entered into a multi-target screening collaboration with Asahi Kasei Pharma for several ion channel targets. Evotec will use its ion channel platform to identify inhibitors of multiple targets. Financial terms were not disclosed.
 
Dr. Mario Polywka, chief operating officer of Evotec, said, “We are extremely pleased that Asahi Kasei Pharma has decided to undertake these projects with Evotec. Our expertise and platform on ion channel drug discovery has proven to add significant value to our partner’s programs and we look forward to supporting Asahi Kasei Pharma in their own ion channel drug discovery efforts.”